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INTRODUCTION 
Ever since the dwan of modern medical core Surgical practice, the 
tracheal intubation techniques in Anaesthetic care has rapidly evolved 
and still evolving into newer modalities. The importance of tracheal 
intubation in securing airway is obvious and needs no emphasis. 
The evolution of tracheal intubation, though there are evidences as 
early as 1500 BC in Egyptians & Hindu scripts, can be roughly traced 
from 19th century onwards. In early 1870’s, Trendelenberg from Germany 
performed the first endotracheal Anaesthesia in Man. McEwen in 1878 
successfully performed the first elective endotracheal intubation for 
anaesthesia (1). Tracheostomy and Intubation were widely used in the 
first world war. The invention of First Anaesthetic Laryngoscope in 1913 
by Jackson and further modification by Magill, Miller and Macintosh 
accelerated the script from Invasive Tracheotomy/Tracheostomy 
intubation to Non Invasive Non-Surgical orotracheal route. 
Not every airway lends itself easier for orotracheal intubation. A 
certain group of patients present with difficult airway in both emergency 
and elective settings that a conventional orotracheal intubation using 
Laryngoscope is difficult to perform. Further, there is an additional risk 
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of loss of Muscle tone and consequent Airway obstruction when General 
Anaesthesia is induced in these patients. 
A breakthrough technique for successful intubation in the above 
described group of patients with difficult airway is the Awake Fiberoptic 
Intubation (AFOI) which has been in practice since 1960’s and gaining 
wider popularity in the management of Difficult Airways. Nowadays, the 
Fiberoptic intubation has become the instrument of first choice in difficult  
intubation cases particularly after the publication of the American society 
of Anaesthesiologists (ASA) guidelines in Difficult Airway 
Management(2). Further Awake Fiberoptic Intubation is safe with a 
higher success rate due to the following reasons. 
i. Preserved Muscle tone avoids airway collapse and keeps the 
airway patent. 
ii. Spontaneous breathing on command can open the obstructed 
airway passages. 
iii. Chances of desaturation is minimal in awake state/spontaneous 
breathing (3). 
Endotracheal Intubation using a Fiberoptic bronchoscope in the 
Awake State, if performed without proper sedation, can be an extremely 
unpleasant and discomforting experience for the patient. At present, 
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various classes of drugs are used for providing sedation during Awake 
Fiberoptic Intubation. They are, 
i. Benzodiazepine(Midazolam) 
ii. Propofol 
iii. Alpha2argonists (clonidine &Dexmedetomidine) 
iv. Opioids (Fentanyl and Remifentanyl) 
v. Ketamine. 
The above mentioned drugs are either used alone or in combination 
with others. An Ideal sedative for the AFOI should provide, 
i. Patient comfort 
ii. Anxiolysis 
iii. Amnesia 
iv. Patent airway with stable Hemodynamic 
v. Attenuated airway reflexes / Antitussive properties. 
The search for the Ideal sedative drug or a combination of them 
and their dosage for sedation during AFOI still continue. 
This study aims to test the efficacy and efficiency of 
Dexmedetomidine and Fentanyl on various parameters for sedation 
during Awake Fiberoptic Intubation. 
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OBJECTIVES OF THE STUDY 
 
1. To study, obtain results and compare the efficiency and efficacy of 
Dexmedetomidine (1ug/kg) and Fentanyl (2ug/kg) for sedation 
during Awake Fiberoptic intubation. 
2. To study the patient’s comfort and compliance for intubation in 
terms of COUGH SCORE and POST INTUBATION SCORE for 
both drugs. 
3. To study the depth and quality of sedation in terms of RAMSEY 
SEDATION SCORE for both drugs. 
4. To study the events of desaturation throughout the procedure using 
SpO2 (Peripheral Capillary Oxygen saturation) for both drugs. 
5. To study the changes in Baseline Heart Rate and the Post 
intubation Heart Rate for both drugs. 
6. To study the changes in Baseline Mean Arterial pressure and the 
Post intubation Mean Arterial Pressure for both drugs. 
7. To look for any side effects of both drugs. 
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REVIEW OF LITERATURE 
AWAKE FIBEROPTIC INTUBATION 
INDICATIONS: 
1. anticipated difficult airway or difficult intubation, 
 Previous history of difficult intubation 
 Suspected difficult airway from patients history and physical 
examination 
 Presence of abnormalities like temporo mandibular joint ankylosis, 
obesity, micrognathia. 
2. Prevention of aspiration in high risk patients. 
3. Avoidance of cervical spine movement in patients with suspected 
cervical spine injury. 
4. Therapeautic and diagnostic applications 
 Clearing of airway secretions 
 Unexplained high airway pressure and hypoxemic conditions 
 Observation of vocal cord paralysis, tracheomalacia, airway 
stenosis 
 Correct positioning of endotracheal tubes 
 Endotracheal tube exchange 
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 Use in supraglottic airway devices, retrograde intubation. 
5. Prevention of traumatic effects of oral or nasal intubation (loose tooth, 
nasal polyps, dental prosthesis). 
6. Routine intubation. 
CONTRINDICATIONS FOR AFOI 
1. Uncooperative patient 
2. Untrained anaesthetist or endoscopist 
3. Equipment failure 
4. Severe upper airway obstruction like foreign body - may be used 
for diagnostic purposes 
5. Massive trauma leading to disruption of upper airway 
6. Perilaryngeal abcess / mass, vocal cord damage are moderate/ 
relative contraindications. 
EQUIPMENTS 
1. FIBEROPTIC BRONCHOSCOPE 
The components of a fiberoptic bronchoscope include, 
a. Eyepiece 
b. Control section comprising 
Angulation lever 
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Suction port 
Working channel port 
c. Insertion cord 
d. Universal cord 
 
Figure showing parts of fiberoptic bronchoscope 
The eyepiece comprises of lens and a focusing ring which can be 
adjusted to sharpen the image to the operator. A video camera can be 
attached to it. 
The control section which is the working handle of the 
bronchoscope. 
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The angulation lever flexes or deflexes the distal tip of the 
bronchoscope. The rotational movement of bronchoscope with 
flexion/deflextion of distal tip help it to achieve the 360˚ panoramic view. 
The suction port valve when pressed clears secretion. 
The working channel port provides for injection of drugs/ 
fluids.eg- local anaesthetic drugs can be instilled in the spray as we go 
technique. 
 
Figure showing the parts of working channels of fiberoptic 
bronchoscope 
The insertion cord comprises of light guide bundle, fibroptic 
bundle, angulation wires and the working channel encased in a smooth 
plastic shell and running from the handle to the tip of the fiberoptic 
bronchoscope. 
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The light guide bundle consists of 25,000-30,000 non coherent 
glass fibres which are around 25-30 micron meter in diameter and they 
transmit the light towards tip. 
There are two angulation wires controlled by angulation lever in 
the control section which helps in flexing/deflexing the distal tip of 
Fiberoptic bronchoscope. Up and down movement of angulation lever 
allows tip of FOB to move in opposite direction by 240◦-350◦. 
The working channel running from the handle to the tip of 
fiberoptic bronchoscope has a diameter of about 1.2-2.8 mm. The tip of 
bronchoscope has an objective lens-2mm in diameter with a fixed focal 
and short field of view (75◦-120˚). 
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The universal cord helps in transmitting light from the light source 
to fiberoptic bronchoscope 
 
Figure showing universal cord connecting light source to fiberoptic 
bronchoscope. 
PRINCIPLE OF FIBEROPTIC BRONCHOSCOPE 
 
INCIDENT LIGHT BEAM TRANSMITTED 
THROUGH LIGHT GUIDE BUNDLES
ILLUMINATES THE TARGET STRUCTURES
DEPENDING UPON THE OPTICAL PROPERTIES 
OF TISSUE, LIGHT PARTIALLY ABSORBED, 
PARTIALLY SCATTERED AND REFLECTED
THE SCATTERED AND REFLECTED  
LIGHT/PHOTONS ENTER THE OBJECTIVE LENS 
TO BE TRANSMITTED TO THE EYE PIECE
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The quality of image depends on, 
a. Objective and eyepiece lens 
b. Intensity of light 
c. Density and number of glass fibres in the light guide and fiberoptic 
bundles 
The fiberoptic bronchoscope cart forms a vital part of difficult 
airway management and should be kept always ready. The cart should 
ideally have, 
a. clean fiberoptic bronchoscope 
b. light source 
c. video monitor 
d. bronchoscope swivel adapters 
e. endoscopy masks 
f. oral airway/nasopharyngeal airway 
g. cotton tipped swabs, gauzes, atomizers 
h. local anaesthetics (2% and 4% lignocaine) 
I. suction catheters 
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Figures showing bronchoscope inserted through swivel 
connector in facemask and endoscopy mask respectively. 
  
13 
 
ENDOTRACHEAL TUBES: 
The ETT is a device that is inserted into the trachea to deliver gases 
and vapour to and from lungs (4). The ETT have been most vital part in 
securing airway since advent of general anaesthesia. 
Parts of ETT 
ETT   comprises of    
1. PATIENT END/DISTAL END 
2. MACHINE END/PROXIMAL END 
The distal end of ETT can be labelled as, 
Bevel 
Murphy eye 
Curve of the tube 
Tracheal tube material 
Markings on the tube 
Tube cuff 
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The distal end is inserted into the trachea. There is a slanted portion 
at the distal tip called bevel facing left when tube is held in anatomical 
position to facilitate the insertion from right and for better visualisation of 
laryngeal structures. Bevel provides for easy insertion in between vocal 
cords and avoiding their injury. 
Opposite to the bevel there is a hole called murphys eye. An 
important advantage of murphys eye is that it provides for an alternate 
port for gas movement in and out of the tube in case the bevel gets 
blocked. 
 
Figure showing the distal end of ETT 
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The ETT have a preformed curve matching the anatomical curve of 
the airway. It resembles an arc of a circle with radius of curvature of 
140±20 mm. 
The markings on the tube include, 
1. A longitudinal line running throughout the length of tube which is 
radio opaque for indicating the correct placement in x ray. 
2. A transverse black line just above cuff helps in ideal insertion of 
correct length of the tube so that the black line is visible just above 
the larynx. This ensures that tube is neither too in nor too out of 
larynx. 
3. Marking describing oral or nasal route of intubation, tracheal tube 
size, name of manufacturer. 
ETT is mainly made of red rubber/natural latex or PVC. The red 
rubber/ latex tubes can be reused after sterilisation but may be allergic 
and irritant. The PVC ETT are non irritant, disposable, transparent and in 
expensive and most commonly used. 
Ideal tube size in average adult male is 8.5 mm ID and for adult 
female is 7.5mm 
An inflatable sleeve near the patient end is called cuff. An inflated 
cuff seals the space between tube and tracheal wall. The cuff is inflated 
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by an inflation tube with pilot balloon which has a one way inflation 
valve .There are two types of cuff, 
1. Low volume, high pressure cuff 
2. High volume, low pressure cuff 
The low volume high pressure cuff are made of thick rubber with 
low compliance and require a higher pressure to inflate with a relatively 
lower volume. They inflate in a circular fashion rather than conforming to 
shape of trachea. They provide better protection against aspiration and 
better visibility during intubation. However the higher pressure can be 
transmitted to the tracheal wall thereby reducing the tracheal wall 
mucosal pressure to critical levels leading to mucosal ischemia, scarring 
and tracheal stenosis in case of prolonged use. 
The high volume, low pressure cuff are made of thin inelastic PVC 
material and has a higher compliance. This type of cuff conforms to 
shape of trachea with large area of contact along the wall and exerts little 
pressure on the tracheal wall mucosa and thus can be used for prolong 
periods. Pressure within cuff can therefore be kept much lower and can 
achieve a seal with minimal risk of mucosal blood flow occlusion.(5) 
.However these types of cuff may be more difficult to insert as the larger 
area of contact obscures view of tube tip. Many microfolds persist in cuff 
creating small channel even after a good seal is achieved resulting in 
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entry of pharyngeal contents into the trachea resulting in ventilator 
associated pneumonia. 
 
The recommended pressure on lateral wall of trachea is 18-25 mm 
Hg in normal adults. 
The PROXIMAL END of ETT projects from the patient and 
receives the connector. It has a 15mm male fitting. The size of connector 
and ETT should be same in ID. The straight and 90˚ curved connectors 
are commonly used (6). The proximal end of connector is attached to 
catheter mounts which are made up of a metal tube or plastic tube which 
are connected to the breathing circuit. 
AWAKE FIBEROPTIC INTUBATION- PROCEDURE 
The awake fiberoptic intubation technique is usually performed in 
presence of a difficult airway or anticipated difficult airway. Thus 
assessment of airway becomes the first vital part in any mode of 
intubation. The two widely used airway assessment techniques are, 
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a. 1-2-3 rule 
b. Modified mallampatti  classification 
1-2-3 rule is 
1. Ability to insinuate tip of 1 finger into temporomandibular joint 
space during opening and closing of mouth in front of tragus. 
2. Atleast 2 finger breadth between upper and lower incisors 
indicating adequate space between jaws for introduction of 
laryngoscope blade and ETT. 
3. A Thyromental distance of more than three finger breadth 
measured between thyroid notch and symphysis menti. 
MODIFIED MALLAMPATI CLASSIFICATION 
 
Figure showing Modified Mallampati Classification 
Once the decision to undertake awake fiberoptic intubation is 
taken, the following steps are mandatory. 
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a. Psychological preparation 
b. General preparation 
c. Pharmacological preparation 
d. Intubation using fiberoptic bronchoscope 
PSYCHOLOGICAL PREPARATION: 
Winning the patients confidence and cooperation is particularly 
important when endo tracheal intubation is planned in awake state (7). 
The preanaesthetic time is ideal for psychological preparation. 
Anaesthesiologist must explain to the patient using less medical terms. 
Further a written informed consent detailing the whole procedure should 
be obtained. 
GENERAL PREPARATION: 
Intravenous access is secured using an 18 gauge IV cannula. 
Monitors are connected to record the baseline heart rate, blood pressure, 
pulse oximetry, electrocardiography. A difficult airway cart, oxygen 
delivery system, suction apparatus, emergency drug tray, drugs like local 
anaesthetics, vasoconstrictors should be kept ready. 
PHARMACOLOGICAL PREPARATION: 
Pharmacological preparation involves administration of Antisialogogues 
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Topicalization of airway 
Sedatives 
Vasoconstrictors- if nasal route is chosen 
ANTISIALOGOUGES 
AFOI requires a clearly visualised airway without secretions. 
Further they prevent dilution of local anaesthetics, washing of topical 
agents down the esophagus and formation of secretion barrier between 
local anaesthetics and airway mucosa. Glycopyrrolate at a dose of 4 
µg/kg is commonly used. 
LOCAL ANAESHESIA OF THE AIRWAY 
Anaesthesia of airway can be achieved by 
Topical lignocaine 
Nerve blocks 
TOPICAL LIGNOCAINE: 
Upper airway: 
Using a lidocaine spray 10%- the palate, valleculae, tonsillar 
pillars, epiglottis and upper larynx can be anaesthetised. 
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Figure showing 10% lignocaine spray 
Lower airway: 
In recent days topical anaesthesia is achieved using, 
Aerosol method, 
Spray as you go technique using fiberoptic bronchoscope during 
intubation procedure. 
AEROSOL METHOD- 
Involves the administration of a nebulised lidocaine (4ml 4%) by 
facemask 
Has an advantage of topicalizing airway without needling. 
 
Figure showing nebulization of lower airway by aerosol method 
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SPRAY AS YOU GO TECHNIQUE: 
The spray as you go technique is often used as a supplementary 
local anaesthesia technique when the patient has partial or nil pharyngeal 
or transtracheal anaesthesia. 
In this method a quick pulse of 1 ml 2-4% lidocaine is injected 
through the working channel of fiberoptic bronchoscope, when the tip of 
the bronchoscope reaches areas with insufficient anaesthesia. 
The suction procedure has to be avoided during this technique so 
that the local anaesthetic is not lost. 
Another method is to pass an epidural catheter through the working 
channel of FOB and extend the catheter tip 1 cm beyond FOB tip. A 
syringe is now attached and LA is injected. The spray goes further 
distance away preventing obscuration of view. 
 
Figure showing epidural catheter inserted in bronchoscope for spray 
as you go technique 
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NERVE BLOCKS: 
The commonly used nerve block for airway anaesthetisation are 
Glossopharyngeal nerve block 
 Transtracheal block 
 Superior laryngeal nerve block 
The nerve blocks are generally used in a patient who is not 
cooperative or with limited mouth opening or as a rescue method when 
hemodynamics changes and cough due to topical application of local 
anaesthetics are undesirable. 
The glossopharyngeal nerve cranial nerve (IX) , Supplies sensory 
innervations of soft palate, the posterior third of the tongue, tonsils and 
the pharyngeal mucosa and occasionally the lingual surface of the 
epiglottis(8), which are all the afferent components of gag reflex. The 
glossopharyngeal nerve is bilaterally blocked by injecting 2ml lidocaine 
at the base of each anterior tonsillar pillar. Alternatively a pledget soaked 
in local anaesthetic is to be kept in piriform fossa each side for 5-10 
minutes. 
24 
 
 
Figure showing glossopharyngeal nerve block  
The transtracheal block is usually done just prior to start of FOB 
intubation. The procedure involves taking of 2-4ml of 4% lignocaine in 
10ml syringe with 23 G needle and cricothyroid membrane is pierced 
with needle in posterior, perpendicular to the floor direction. A sudden 
loss of resistance is felt when the needle enters the trachea, after which 
the local anaesthetic is rapidly injected and needle is quickly withdrawn. 
A bout of cough suddenly follows which helps spread of local 
anaesthetics to the entire trachea between carina and vocal cords. The 
complications of transtracheal block include tracheal injury, subcutaneous 
emphysema and bleeding. 
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Figure showing transtracheal block 
The superior and inferior laryngeal branches of the vagus supplies 
sensory innervations of the laryngopharynx . the internal division of the 
superior laryngeal nerve is sensory to base of the tongue, vallecula, 
epiglottis, pyriform recess and the laryngeal vestibule above the vocal 
cords. The recuurent laryngeal nerve, an inferior branch of vagus, is 
sensory to the area below the vocal cord . the internal branch of superior 
laryngeal nerve is blocked between the greater cornua of the hyoid bone 
and the superior cornua of the thyroid cartilage as the nerve passes 
through the thyrohyoid membrane to the submucosa of the piriform sinus. 
A 23 G needle with a syringe containing 5ml of 1% lidocaine is inserted 
until if rests on the lateral most part of the hyoid bone and then it is 
withdrawn a bit and in the inferior direction, walked off the greater 
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cornua and advanced through the thyrohyoid membrane, which gives a 
slightly resistant felt and 2ml of local anaesthetic is injected. 
 
Figure showing nerve supply of larynx and superior laryngeal nerve 
block 
SEDATIVES: 
Unless properly sedated intubation is extremely discomforting and 
unpleasant experience for the patient. Thus the use of sedatives form a 
vital part of the pharmacological preparation. 
Ideal sedative should provide, 
Patient comfort and cooperation 
Anxiolysis 
Amnesia 
Attenuated airway reflexes / antitussive properties 
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Stable hemodynamics 
Maintenance of patent airway with spontaneous ventilation. 
The available choice of drugs include, 
Midazolam    1-2mg 
Propofol     25-75µg/kg/min 
Dexmedetomidine  0.2-0.7µg/kg/hr 
Fentanyl          0.7-1.5µg/kg 
Remifentanyl 0.01-0.05 µg/kg bolus followed by 0.03- 
0.05µg/kg/min 
Ketamine          0.025-0.15 mg/kg 
The choice and use of above sedatives varies according to the 
patient and clinical operative settings. For all drugs careful titration 
should be followed. Extreme caution is warranted when a combination of 
agent is used as it could be synergetic. 
This study aims to test the efficacy of alpha 2 agonist 
Dexmedetomidine and opioid Fentanyl for sedation during awake 
fiberoptic intubation. 
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VASOCONSTRICTORS 
When intubation is done through nasal route the vasoconstrictors 
are administered to reduce the risk of epistaxis. Commonly used drugs 
include, 
Oxymetazoline 0.05% 
Xylometazoline 0.1% 
Phenylephrine 0.5% 
Co-phenylcaine (lidocaine and phenylephrine 0.5%) 
Antiemetic such as Ondansetron is used to reduce gag reflex during 
the procedure. 
The nasal mucosa is anaesthetised and vasoconstricted by packing 
them with swabs soaked in either a 4% cocaine solution or a combination 
of lidocaine and phenylephrine (1cc of phenylephrine 3 cc of lidocaine). 
Vasoconstrictors should be cautiously used in pregnant patients due to 
risk of uteroplacental perfusion reduction and in patients with 
cardiovascular diseases due to risk of angina pectoris and myocardial 
infarction (9, 10) 
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INTUBATION USING THE FIBEROPTIC BRONCHOSCOPE 
Once the patient and the airway is prepared as described 
previously, the anesthetist has to decide whether a nasal or oral approach 
to be used. In general the nasal route is easier for fiberoptic bronchoscope 
intubation because the angle or curvature of the endotracheal tube 
naturally coincide with that of the patients upper airway. Thus it becomes 
easy to maintain a midline position and direct the scope into trachea (11). 
The advantages in a nasal route include reduced gag reflex, free 
from biting/chewing of the scope by the patient. On the other hand there 
are risks of bleeding when the nasal route is used. 
With the table or bed position at its lowest setting, the patient is kept 
supine. A step stool is used to keep the FOB straight. The next steps are 
as follows, 
1. An endotracheal tube made up a polyvinyl chloride, which is atleast 
1.5mm larger than the diameter of the insertion cord of the insertion 
cord of the Fiberoptic bronchoscope is preloaded on it. 
2. For a nasal intubation, coagulation disorders should be ruled out. A 
well lubricated soft nasal airway can be used to gauge the nasal 
patency as well as for gradual dilation in a well prepared 
anaesthetised and vasoconstricted nasal pathway. The nasal airway is 
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then removed and the Fiberoptic bronchoscope tip can be directly 
introduced into the nose. 
3. The handle of the Fiberoptic bronchoscope is held in non dominant 
hand and the tip of the fiberoptic bronchoscope is held in the 
dominant hand as passing/manoeuvring the tip is an intricate 
process. The tip of the Fiberoptic bronchoscope is held between the 
thumb and next two fingers of the dominant hand just like holding a 
pen. 
The non dominant hand holding the handle of the Fiberoptic 
bronchoscope is held high to prevent  bending of the insertion cord. 
The lever has to be pressed to look up and down and for looking 
left or right, the grip on the distal FOB insertion is loosened between the 
thumb and the next two fingers and the handle section in the non-
dominant hand is rotated counter clockwise or clockwise respectively. 
Further for proper identification of structures, the recognizable landmark 
are kept in the centre of the view along the desired path. 
4. The fiberoptic bronchoscope’s tip is passed down the nasopharynx, 
then the uvula and further downwards to the epiglottis, which is the 
first landmark. The lever in the handle can be pressed to look 
upwards for visualization of the structures. If the structures are not 
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identifiable, the bronchoscope is slowly retracted until a 
recognizable structures is found and then inserted downwards. 
5. After the identification of epiglottis, the tip is inserted into the 
laryngeal opening. If the topical anaesthetics of the airway is not 
adequate, using the spray as we go technique, 1ml of 2% lignocaine 
can be instilled through the working port of the fiberoptic 
bronchoscope. This may precipitate a bout of cough and so prior 
information must be given to the patient. After 2-3 minutes, the local 
anaesthetics act and the tip is further introduced into the subglottic 
space. 
6. Once in the subglottic space, the trachea which is the second 
landmark is confirmed by the presence of tracheal rings. Once 
trachea is identified a further 1ml of 2% lidocaine is instilled. 
7. After the anaesthetisation of tracheal mucosa, the tip of 
bronchoscope is pushed downwards until the bifurcation of trachea 
the carnia is visualised. The carina is the third landmark in the 
intubation procedure. Another dose of local anaesthetic is instilled. 
8. After 1-2 minutes the preloaded endotracheal tube is slided forward 
on the insertion cord of the Fiberoptic bronchoscope with the 
murphys eye oriented anteriorly to prevent it from getting hung up 
on arytenoids. An important aspect that should be noted is that the 
Fiberoptic bronchoscope should not be allowed to go forward as the 
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ETT slides forward. This can be ensured by keeping the bifurcation 
in the view at all times. 
9. The breathing sounds of the patient are listened to judge when the 
ETT is near the larynx. The patient is then asked to take some deep 
breaths so that the vocal cords move away to admit admit the ETT.  
Once the ETT has gone beyond the vocal cords into the trachea, the 
fiberoptic bronchoscope’s tracheal view can be obtained. 
10. The endotracheal tube is further slided forwards upto two or three 
rings above the carina. The cuff of the ETT is inflated and the ETT 
is stabilised in the trachea. 
11. The fiberoptic bronchoscope is removed with tip in the neutral 
position once the endotracheal tube is stabilised. The tip in the 
neutral position while retraction prevents damage. Once the 
bronchoscope is removed the ventilating system is attached to the 
endotracheal tube and the further steps in the general anaesthesia can 
be initiated. This marks the end of intubation procedure. The end 
tidal CO2(ETCO2) should be monitored 
While the fiberoptic bronchoscope is slided forward into the 
airway, if there are excessive oropharyngeal secretions or blood 
obscuring the view, suction can be applied continuously or intermittently 
providing a clear view. 
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Figure showing Steps of fiberoptic bronchoscope intubation 
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If the tip of fiberoptic bronchoscope gets fogged due to warm 
exhaled air, defogging can be done by touching the tip of FOB onto the 
mucosa or by removing and dipping into warm saline solution. 
If the cough or gag is persistent as the fiberoptic bronchoscope is 
advanced, the local anesthetic blocks has to be repeated or the “spray as 
you go” technique can be used. 
Care should be taken to ensure that all the vital parameters of the 
patient including blood pressure, heart rate, oxygen saturation, ECG are 
monitored continuously and are within acceptable limits. 
The fiberoptic bronchoscope intubation can be combined with 
other devices so that better airway control, higher rate of success, 
reduction of failed intubation can be achieved. The combination devices 
include, 
a. Endoscopic masks 
b. Nasopharyngeal airways 
c. Supraglottic airway devices like laryngeal mask 
airway (LMA). 
Endoscopy masks allow for spontaneous or controlled ventilation 
while both nasal and oral intubation can be performed. They have a port 
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for allowing FOB to pass through a diaphragm which is airtight 
preventing airleak while ventilating the patients. 
The use of short and soft nasopharyngeal airway helps in gradual 
dilation of nostrils after proper lubrication and facilitates the subsequent 
pass through of the fiberoptic bronchoscope. 
Intubating supraglottic airway device acts as a conduit for blind 
passage of an ETT into the trachea. The success rate for FOB-intubating 
SGA combination is greater than 98%. 
COMPLICATIONS OF FOB INTUBATION: 
The various complications that are commonly encountered in FOB 
intubation include, 
 Nasal bleeding/epistaxis 
 Tissue trauma 
 Hoarseness of voice 
 Sore throat 
 Laryngospasm and bronchospasm 
 Aspiration 
 Damage to bronchoscope by chewing, biting etc, (12). 
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PHARMACOLOGICAL REVIEW 
This dissertation aims to compare the efficiency of two drugs, 
1. Dexmedetomidine 
2. Fentanyl 
For sedation during awake fiberoptic intubation. 
DEXMEDETOMIDINE: 
It is a potent alpha-2 adrenergic agonist. It was approved by FDA in 
1999 for use in humans as analgesic and for ICU sedation and in 2008 for 
sedation in non-intubated patients. 
STRUCTURE: 
 
Dexmedetomidine is chemically described as (+)-4-(S)-[α-(2,3-
dimethyl)ethyl]H-Imidazole monohydrochloride 
It has molecular weight of 236.7 
Its empirical formula is C13H16N2.HCL 
The Pka of Dexmedetomidine is 7.1 
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PRESENTATION: 
Trade names under which Dexmedetomidine hydrochloride are 
marketed include precedex, dexdor, and dexdomitor. 
Dexmedetomidine hydrochloride is a sterile, nonpyrogenic solution 
suitable for intravenous infusion. 
DOSE: 
Dose of Dexmedetomidine for sedation is, 
Loading dose-1µg/kg over ten minutes 
Maintenance dose-0.2 to 0.7 µg/kg/hour 
For patients over 65 years of age, dose reduction should be 
considered. 
In this study Dexmedetomidine is used at a dose of 1µg/kg given as 
a loading infusion. 
POTENCY: 
Dexmedetomidine is a potent alpha-2 adrenergic agonist which is 
shorter acting than clonidine. It is much more selective for α2 vs. 
α1receptors than clonidine. 
Dexmedetomidine- 1620:1(13) 
Clonidine-                 220:1 
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MECHANISM OF ACTION: 
Dexmedetomidine is a highly selective potent α2 adrenergic agonist. 
It has sedative, analgesic, anxiolytic and anti sialogouge properties with 
minimal respiratory depression. 
Dexmedetomidine acts upon the pontine locus ceruleus which is an 
important centre for sympathetic system function, vigilance, analgesia 
and arousal. The sedation, analgesic effect produced is largerly due to the 
inhibition of this nucleus. 
 
 
Figure showing mechanism of action of dexmedetomidine  
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PHARMACOKINETICS: 
Dexmedetomidine has a rapid distribution phase, with a distribution 
half life of approximately six minutes, and terminal elimination half life 
of approximately 2 hours 
Peak plasma concentration-0.3 to 0.5 ng/ml. 
Protein bound-94% 
Volume of distribution 118 L. 
  
Dexmedetomidine acts upon α-2 receptors on presynapse
activation of G proteins
second messenger system activation
inhibition of adenylate cyclase
↓ camp
changes in phosphorylation of target proteins that are dependent on 
camp kinases
modulation of ion channel activity efflux of K+, ↓INnflux of Ca2+ 
hyperpolarisation
inhibitory effect on secretion of neurotransmitters(nor-
epinephrine)
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METABOLISM: 
Dexmedetomidine is metabolised by liver via glucuronidation and 
CYP2-A6 
Metabolites include 3-hydrox,3-carboxy, 3- hydroxyl N-methyl, 3-
carboxy N-methyl and N-methyl O-glucuronide Dexmedetomidine. 
Total body clearance-39L/hr. 
Excretion –urine (95%) 
Feces (4%). 
EFFECTS: 
CENTRAL NERVOUS SYSTEM: 
Presynaptic action of α-2 receptors inhibits the release of 
norepinephrine thereby terminating the propagation of pain signals. Post 
synaptic activation of α-2 receptors in the CNS inhibits sympathetic 
activity. Combained these effects produce analgesia, sedation and 
anxiolysis (14). 
The sedation produced by α-2 agonists differ from sedation 
produced by drugs like midazolam that act on GABA receptors. α-2 
agonists decrease sympathetic system activity and level of arousal. This 
provides a calm patient who can be easily aroused to full consciousness. 
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On the other hand, drugs acting upon GABA produce a clouding of 
consciousness and can also cause paradoxical agitation as well as 
tolerance and dependence (15). 
CARDIOVASCULAR SYSTEM: 
Higher concentration of Dexmedetomidine causes bradycardia and a 
biphasic dose-response relation for mean arterial pressure. 
Premedication with Dexmedetomidine attenuates the hemodynamic 
responses to endotracheal intubation and decreases plasma catecholamine 
levels. 
RESPIRATORY SYSTEM: 
Dexmedetomidine does not cause clinically relevant respiratory 
depression or exhibits only minimal respiratory depression unlike other 
opioid sedatives. This unique feature enables it to be used as a sedative 
for patients with difficult airway during AFOI, in mechanically ventilated 
patients in intensive care units. 
Dexmedetomidine decreases the mean alveolar concentration 
(MAC) for volatile anaesthetics. Isoflurane MAC was decreased 35% and 
48% by Dexmedetomidine plasma concentration of 0.3ng/ml and 
0.6ng/ml respectively (16). 
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GASTROINTESTINAL SYSTEM: 
Reduced salivary secretion-anti sialogouge property enables clear 
visualisation of airway structures. 
Decrease bowel motility. 
EXCRETORY SYSTEM: 
Inhibition of rennin release. 
Increased glomerular filtration rate. 
Increased secretion of sodium and water in the kidney. 
ENDOCRINE CHANGES 
Decreased insulin release from the pancreas (17). 
DRUG INTERACTION: 
Dexmedetomidine may enhance the effects of other sedatives and 
anaesthetics when co-administered 
Drugs that reduce heart rate and blood pressure like β-blockers 
should be cautiously used when co administered with Dexmedetomidine. 
ANTAGONISTS: 
Atipamezole is a specific and selective α-2 receptor anatagonist 
that effectively and rapidly reverses the sedative and cardiovascular 
effects of intravenous Dexmedetomidine (18). 
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FENTANYL: 
Fentanyl is a synthetic opioid, a tertiary amine and phenyl piperidine 
derivative. 
STRUCTURE: 
 
Molecular formula-C22H28N2O 
Molecular weight-336.479 g/mol 
Fentanyl is chemically described as N-(1-Phenyl-4-piperidyl) 
propionanilide hydrochloride. 
Pka of Fentanyl-8.4. 
PRESENTATION: 
1. Fentanyl is available as transdermal patches at various doses 
25/50/75/100 µg delivered per hour over a period of 72 hours. 
2. As a clear, colourless solution for injection containing 50µg/ml of 
Fentanyl citrate. 
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3. Fentanyl citrate is also available as lollipop sticks which slowly 
dissolve in mouth-in dosages 200µg, 400µg, 600µg, 800µg, 1200µg 
and 1600µg. 
ANALGESIC PROPERTY: 
Fentanyl is 1000 times more potent than Meperidine (19), 75-125 
times more potent than Morphine. 
100µg of Fentanyl is equal to 75mg of Meperidine, 10mg of 
Morphine. 
MECHANISM OF ACTION: 
Fentanyl is a highly selective opioid µ receptor agonist which is 
mainly responsible for producing its analgesic property. Fentanyl 
increases intracellular calcium concentration which in turn increases K+ 
conductance and hyperpolarisation of cell membrane. This results in 
decreased membrane conductance in both pre and post synaptic 
responses. Analgesia is produced principally through interaction with µ 
receptors at supraspinal levels. Fentanyl can also bind to K receptors 
resulting in spinal analgesia, sedation and anaesthesia. 
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PHARMACOKINETICS: 
A single dose of Fentanyl administered intravenously has a rapid 
onset and shorter duration of action than Morphine. There is a distinct 
time lag between the peak plasma Fentanyl concentration and peak 
lowing on the EEG reflecting the delay due to effect site equilibrium time 
between blood and brain for Fentanyl which is 6.4 minutes. 
Fentanyl has a greater lipid solubility resulting in greater 
correlation between plasma concentration of Fentanyl with that of CSF 
concentration. 
The rapid distribution to inactive tissue sites accounts for its 
shorter duration of action. 75% of the initial dose undergoes first pass 
pulmonary uptake (20). This limits the initial amount of drug that reaches 
the systemic circulation and may play an important role in determining 
the pharmacokinetic profile of Fentanyl. 
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Fentanyl has a longer elimination half life than Morphine. 
The volume of distribution is 0.88-4.4L/kg. 
METABOLISM: 
Fentanyl is extensively metabolised by N-demethylation producing 
norfentanyl, hydroxypropionyl Fentanyl and hydroxypropionyl-
norfentanyl. 
Norfentanyl is the principal metabolite of Fentanyl in humans. 
Other metabolites have minimal pharmacological activity. 
Cytochrome P-450 3A4 plays predominant role in Fentanyl 
metabolism (21). 
EXCRETION: 
Around less than 10% of Fentanyl is excreted unchanged in urine. 
Clearance is 0.4-1.5L/Min. 
Clearance is decreased in patients with hepatic impairment. 
EFFECTS: 
RESPIRATORY SYSTEM: 
Fentanyl at 1-2µg /kg decreases respiratory rate and increases tidal 
volume When doses are increased above 3µg/kg it decreases both 
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respiratory rate and tidal volume and ventilator response to hypoxia and 
hypercarbia. 
When large doses are given rapid IV it can produce chest wall 
rigidity, due to its effect on µ receptors located on GABA interneurons. 
Can be controlled by use of muscle relaxants. 
CENTRAL NERVOUS SYSTEM: 
It is a CNS depressant. 
In low doses 1-2µg/kg it is devoid of hypnotic and sedative activity. 
Fentanyl produces miosis due to stimulation of Edinger Westphal 
nucleus. 
CARDIOVASCULAR SYSTEM: 
DOSE CARDIOVASCULAR EFFECTS 
1µg/kg No significant effect on papillary muscles 
7µg/kg ↓heart rate 
10µg/kg Myocardial contractility reduced by 50% 
20-25µg/kg ↓ hear rate, MAP, systemic and pulmonary vascular resistance 
75µg/kg Hemodynamic stability 
 
Table 1 
  
49 
 
GASTROINTESTINAL TRACT: 
Fentanyl increases common bile duct pressure by causing spasm of 
sphincter of oddi. 
It causes nausea, vomiting and decreases GI motility. 
GENITOURINARY SYSTEM: 
It increases the tone of the ureters, bladder detrussor muscle and 
vesicle sphincter causing retention of urine. 
METABOLIC EFFECTS: 
Fentanyl increases plasma epinephrine, cortisol, glucose, free fatty 
acids and growth hormone levels during surgery. 
RELATIONSHIP BETWEEN PLASMA FENTANYL 
CONCENTRATION AND EFFECT (22) 
PLASMA FENTANYL 
CONCENTRATION(ng/ml) 
PHARMACOLOGICAL EFFECT 
>1 Slight analgesia and minimal ventilatory 
depression. 
1-3 Analgesia, 50% decrease in ventilatory 
response to Co2. 
4-10 Analgesia for surgery if combined with N2O. 
>20 Unconscious, satisfactory as sole agent. 
Table 2 
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SIDE EFFECTS: 
The main side effect of concern is respiratory depression, 
intraoperatively and postoperatively (23) due to which continuous 
monitoring is warranted. 
Respiratory depression is related to secondary peak in plasma 
Fentanyl concentration due to elution from muscle. 
Others are nausea, vomiting, pruritis, urinary retention, dependence 
etc.., 
DRUG INTERACTION: 
When Fentanyl is combined with benzodiazepines there is a 
marked synergism in hypnosis and depression of ventilation (24). In 
clinical practise adequate caution is required when co administered. 
CLINICAL REVIEW: 
In a study 60 patients undergoing awake fiberoptic intubation were 
divided into two groups. Group A receiving Dexmedetomidine at 1µg/kg 
over 10 mins and group B receiving Fentanyl at 2 µg/kg over 10 minutes 
for sedation during intubation. They concluded that Dexmedetomidine is 
more effective than Fentanyl in producing better intubating conditions, 
sedation, hemodynamic stability and less desaturation during AFOI (25). 
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In a study 40 patients with anticipated difficult airway and to 
undergo tracheal intubation for elective surgery were randomly divided 
into Dexmedetomidine group 1µg/kg over 10 minutes and propofol target 
controlled infusion group. They concluded that both Dexmedetomidine 
and Propofol TCI are effective for fibroptic intubation but 
Dexmedetomidine allows better tolerance, hemodynamic status and 
preserves a patent airway (26). 
In a study 55 patients were divided into two groups with one group 
receiving Dexmedetomidine with Midazolam 0.02mg/kg and other group 
receiving Midazolam alone @0.05mg/kg for sedation. They concluded 
that patients who received Dexmedetomidine and Midazolam were 
significantly calmer and cooperative during AFOI, more satisfaction with 
fewer adverse effects and no significant hemodynamic differences than 
Midazolam only group (27). 
In a study, 30 oral carcinoma patients with limited mouth opening 
undergoing AFOI for elective surgery were divided into two groups. The 
DEX group with 16 patients received Dexmedetomidine 1µg/kg and the 
Fentanyl group with 14 patients received Fentanyl at a dose of 1 µg/kg. 
They concluded that Dexmedetomidine with topical anaesthesia provides 
significant benefits for AFOI in intubating conditions, patient tolerance, 
hemodynamic response, amnesia and satisfaction (28). 
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In a study four patients with particularly difficult airway underwent 
AFOI with Dexmedetomidine. They reported that Dexmedetomidine 
provides a moderate level of conscious sedation without causing 
respiratory distress or hemodynamic instability during fibroptic 
intubation (29). 
In a study three patients undergoing cervical spine surgery under 
AFOI with Dexmedetomidine sedation reported that intubating conditions 
were acceptable with Dexmedetomidine and topical anaesthesia (30). 
In a study three patients with odontogenic and cervical infection 
undergoing AFOI were sedated with Dexmedetomidine. They reported 
that Dexmedetomidine provided safe and effective sedation and 
anxiolysis (31). 
In a study, a patient with cervical cord compressive lesion and 
raised intracranial pressure undergoing elective excision of a 
cerebellopontine angle lesion had AFOI under Dexmedetomidine 
sedation. They reported Dexmedetomidine facilitated self positioning 
before surgery and no adverse neurological outcomes were reported (32). 
In a study 56 patients undergoing cervical fixation were divided 
into two groups of 26 patients for AFOI. The test group received 
Dexmedetomidine infusion and the control group received normal saline. 
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They reported that group receiving Dexmedetomidine infusion in addition 
to topical anaesthesia during AFOI remained more comfortable than 
group with airway block alone (33). 
In a stud a total of 90 patients, all ASA PS – I, II undergoing AFOI 
were divided into two groups. One group received remifentanyl and other 
group received Dexmedetomidine sedation. Both group received 2% 
lignocaine for topical anaesthesia. They concluded that comfort scales 
and airway events did not differ significantly between the two groups, 
Dexmedetomidine and Remifentanyl exhibit similar efficacy as adjuvant 
therapies for AFOI (34). 
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METHODOLOGY 
Study Pattern: 
This clinical study was conducted in the Department of 
Anesthesiology in association with Department of General Surgery, ENT 
in Govt. Theni Medical College, Theni between 01.08.2017 to 
01.08.2018. Necessary clearances were obtained from the Hospital ethics 
committee for the study. Written Informed consent was obtained from all 
patients. 
A total of 60 patients posted for elective surgery undergoing 
Awake Fiberoptic Intubation were included. 
Patient Selection: 
Inclusion Criteria: 
i. Age Group 18 – 50 years 
ii. ASA – PS I and II 
iii. Mallampati Grading I & II 
Exclusion Criteria: 
 Patients unwilling for the procedure 
 Uncontrolled seizure disorder 
 History of Unstable Angina or MI/Complete Heart block 
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 Resting Heart Rate < 50/min 
 History of allergy to Local Anaesthetic drug 
 History of bleeding disorders 
 Diabetes Mellitus/Systemic Hypertension 
 History of Psychiatric/Neurological disease 
 MPG III and IV 
Equipments: 
1. IV canula and IV fluids 
2. Fiberoptic Bronchoscope of appropriate size 
3. Endotracheal tube of appropriate size 
4. Drugs 
Study agent 
Inj. Dexmedetomidine 
Inj. Fentanyl 
Emergency drugs 
Inj. Adrenaline 
Inj. Atropine 
Inj. Ephedrine 
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Inj. Thiopentone Sodium/Inj. Propofol 
Inj. Succinyl choline 
Others 
i. Inj. Metoclopramide 
ii. Inj. Ranitidine 
iii. Inj. Ondansetrone 
5. Boyle’s Machine 
6. Resuscitation equipments, Oxygen cylinder, AMBU bag, 
Laryngoscope, Endotracheal tubes of different sizes, Suction 
apparatus, and Emergency tray. 
7. Monitoring equipment ECG, NIBP, Pulse Oximetry. 
Methodology: 
A total of 60 patients with ASA I & II and Mallampati grading I & 
II  who were posted for elective surgery like laparoscopic 
appendicectomy, laparoscopic cholecystectomy, Thyroidectomy, 
Parotidectomy, modified radical mastoidectomy,  were selected for the 
study according to the inclusion & exclusion criteria. A well informed 
written consent was obtained from all of them. 
A detailed history, physical examination and routine investigations 
were done for all the patients. IV line was secured with a 18G Cannula. 
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All vital parameters (HR, NIBP, Respiratory Rate, O2 Saturation, and 
ECG) were being continuously monitored. Baseline heart rate and Mean 
Arterial pressure readings were taken. 
Patients were randomly allocated into two groups, 
i. Group A – Receiving Inj. Dexmedetomidine at a dose of 
1ug/kg over 10 min 
ii. Group B – Receiving Inj. Fentanyl at a dose of 2ug/kg over 
10 min 
The total dose of the drug was calculated according to the patient’s 
weight. 
All patients had premedication drugs with tab Alprazolam 0.5 mg 
night before surgery, tab Ranitidine 150 mg and tab Ondansetron 4 mg on 
the morning 2 hours before the surgery Inj. Glycopyrrolate 0.2 mg IV was 
given. Topicalisation of upper and lower airway was accomplished by 
nebulisation with 4% lidocaine 4ml (160mg) for 20 min. Patency of both 
nostrils were tested and nostril with better patency was chosen for Awake 
Nasal Fiberoptic Intubation. Xylometazoline nasal drops and lidocaine 
Jelly were applied to both the nostrils. Oropharynx and Hypophranynx 
were sprayed with two puffs of 10% lidocaine (20mg). Then as per the 
patient’s grouping, Inj. Dexmedetomidine (1ug/kg over 10 min) or Inj. 
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Fentanyl (2ug/kg over 10 min) were infused. At the end of study drug 
Infusion, the level and quality of sedation was assessed using Ramsay 
sedation scale/score. A well lubricated Fibreoptic bronchoscope 
preloaded with appropriate size cuffed Endotracheal tube was kept ready. 
 The grading of sedation as per RAMSAY SEDATION SCORE are 
as follows: 
1. Anxious, Agitated or Restless 
2. Cooperative, oriented and tranquil 
3. Sedated but responds to command 
4. Asleep, brisk glabellar reflex, responds to loud noise 
5. Asleep, Sluggish glabellar reflex, responds to loud noise 
6. Asleep with no response to a painful stimulus 
After achieving RSS>= 2, bronchoscopy was performed 
through Nasal approach. If RSS >=2 could not be achieved after 
the infusion of the study drug Inj. Midazolam 0.05mg/kg was used 
as rescue sedation. 
 Intubation condition was evaluated by COUGH SCORE during 
bronchoscopy 
 Score 1 – no cough 
 Score 2 – Slight cough (no more than 2 cough in sequence) 
 Score 3 – Moderate cough (3-5 coughs in sequence) 
 Score 4 – Severe cough(>5 Coughs in sequence) 
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 Tolerance to intubation was evaluated by the POST INTUBATION 
SCORE after the successful placement of endotracheal tube in the 
trachea. 
 Score 1 -  Co-operative 
 Score 2 – Minimal Resistance 
 Score 3 – Severe resistance 
 Further, Heart rate and Mean Arterial Pressure were noted 
immediately after intubation 
 Oxygen saturation using SpO2 was monitored throughout the 
procedure and the lowest reading was noted. 
 After proper placement of ETT in trachea, general anesthesia was 
induced and surgery was allowed to proceed. 
 During the intubation and post intubation periods, Hypotension, 
Bradycardia and Desaturation were promptly corrected under 
relevant protocols. Hypotension (Decrease in MAP > 20% from 
baseline) was treated with IV fluids and Inj. Ephedrine 6mg IV in 
titrated doses. 
 Oxygen desaturation (SPO2< 95% for > 10 seconds) was treated 
with O2 supplementation. Brady cardia (HR < 60 /min) was treated 
with Atropine. 
 All recordings were tabulated. Numerical data were expressed as 
mean with a standard deviation. The necessary statistical analysis 
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was carried out using the statistical package for the social sciences 
20.0 statistical software package. Numerical data were compared 
between the 2 groups using independent t-test and within the same 
group using paired t-test. Categorical data were compared between 
two groups using chi square test. P value < 0.05 was considered 
statistically significant. Further, for better understanding, necessary 
data’s are also expressed in bar diagrams. 
The following flow chart explains the progress of participants 
through the study. 
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OBSERVATION AND RESULTS 
 
The master chart detailing the age and sex of the patients involved 
in the study, their weight, ASA-PS, categorisation as group-A and group-
B, cough score, post intubation score, Ramsay sedation score, oxygen 
saturation, baseline and post intubation heart rate, baseline and post 
intubation mean arterial pressure is added in annexure. 
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AGE DISTRIBUTION: 
Table 3:  
 
 
The age data of the patients in group-A and group-B were analysed 
using t-test. In group-A (n=30), the mean age was 34.33 years with a 
standard deviation of 8.155 years. In group-B (n=30) the mean age was 
33.60 years with a standard deviation of 7.938 years. The P value was 
0.725 which is greater than 0.05 and hence the age correlation between 
the two groups is statistically not significant. 
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SEX DISTRIBUTION: 
Table 4: 
 
The data regarding the sex in both groups were analysed using the 
chi-square test. In group A (n=30), there were 17 males and 13 females. 
The composition of males and females in group A were 56.7% and 43.3% 
respectively. In group-B (n=30) there were 17 males and 13 females. The 
composition of male and female in group-B were 56.7% and 43.3% 
respectively. The P value was 1 which is greater than 0.05. Hence the sex 
correlation between the two groups is statistically not significant. 
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DISTRIBUTION OF ASA-PS 
Table 5: 
 
The data regarding ASA-PS were analyzed using chi-square test. In 
group-A (n=30) there were 25 patients with ASA-PS I and 5 patients with 
ASA=PS-II. The composition of ASA-PS I  and II in group A were 
83.3% and 16.7%. In group B (n=30) 26 patients with ASA-PS I and 4 
patients with ASA=PS –II . The composition of ASA-PS I and II in group 
B were 86.7% and 13.3% respectively. The P value was 0.718 which is 
greater than 0.05 hence correlation of the data regarding ASA-PS 
between the two groups is statistically not significant. 
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WEIGHT DISTRIBUTION: 
Table 6: 
 
Weight data in both the groups were analyzed using the t test. In 
group-A (n=30), the mean weight was 63.90 kg with a standard deviation 
of 6.216 kg. In group B (n=30), the mean weight was 64.70 kg with a 
standard deviation of 6.309 kg. The P value was 0.623 which is greater 
than 0.05. Hence the weight correlation between the two groups is 
statistically not significant. 
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COUGH SCORE DISTRIBUTION: 
Table 7: 
 
The data regarding cough score in both groups were analyzed using 
chi-square test 
In group-A (n=30) 2 patients had cough score 1 
25 patients had cough score 2 
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3 patients had cough score 3. 
In group-B (n=30), no patient had cough score 1 
3 patient had cough score 2 
27 patient had cough score 3 
No patients from both the groups had severe cough (>5 cough in 
sequence)i.e. cough score 4 
83.3% of the patients in group-A had cough score 2 while 90% of 
the patients in group B had cough score 3 
The P value was 0.001 which is less than 0.05 and hence 
statistically significant 
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POST INTUBATION SCORE DISTRIBUTION: 
Table 8: 
 
The data regarding post intubation scores in both groups were 
analyzed using the chi-square test 
In group A (n=30), 27 patients had the best post intubation score 1 
(co-operative) 
3 patients had the post intubation score 2   (minimal resistance) 
69 
 
No patient had post intubation score 3 (severe resistance) 
In group B (n=30), 3 patients had the best post intubation score, 
score1 
24 patients had the post intubation score2 
3 patients had the post intubation score3 
90% of the patients in group A had the best post intubation score of 
1 whereas 80% of the patients in group B had post intubation score 2 
P value is 0.002 which is less than 0.05 and hence statistically 
significant 
Thus the post intubation score is significantly favorable in group A 
than group B. 
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RAMSAY SEDATION SCORE DISTRIBUTION: 
Table 9: 
 
The data regarding the Ramsay sedation score in both groups were 
analyzed using the chi-square test. 
An RSS ≥2 is considered necessary before intubation. If the RSS is 
< 2 Inj.Midazolam 0.05mg/kg was used as rescue sedation. 
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In group A (n=30) 
 No patient had RSS 1 (Anxious agitated or restless) 
 4 patients had RSS 2 (cooperative, oriented and tranquil) 
 24 patients had RSS 3 (sedated but responds to commands) 
 2 patients had RSS 4(asleep, brisk glabellar reflex, responds to 
loud noise) 
In group B (n=30) 
 2 patient had RSS 1 ( Inj.Midazolam 0.05mg/kg was used as rescue 
sedation) 
 25 patients had RSS 2 
 3 patients had RSS 3 
 No patient had RSS 4 
Further no patients in both groups had an RSS 5 (asleep, sluggish 
glabellar reflex, responds to loud noise) or RSS 6 (asleep, no response to 
painful stimulus) 
80% of patients in group A could achieve an RSS of 3 (sedated and 
responds to commands) while 83.3% of patients in group B achieved an 
RSS of 2 (cooperative oriented and tranquil) 
The P value is 0.004 which is less than 0.05 and hence statistically 
significant. 
Thus Ramsay  sedation score is significantly favorable for group A 
than group B. 
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DISTRIBUTION OF OXYGEN SATURATION DATA: 
Table 10: 
 
The data regarding oxygen saturation in both groups were analyzed 
using t-test 
In this study, the SpO2 value which is  lowest during the entire 
intubation procedure (from study drug infusion to completion of 
intubation) was taken. If SpO2 was less than or equal 95%, it was 
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considered to be a desaturation event and treated promptly with oxygen 
supplementation. 
In group A (n=30), the mean SpO2 value was 96.6% with a 
standard deviation of 1.653% 
In group B (n=30), the mean SpO2 value was 93.10% with a 
standard deviation of 2.107% 
The P value was 0.000 which was less than 0.05 and hence 
statistically significant 
Thus it can be established that desaturation events were 
significantly less in group A than group B. 
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HEART RATE DATA DISTRIBUTION: 
Table 11: 
 
The data regarding baseline and post-intubation heart rate were 
analyzed using t test 
The mean base line heart rate of 
Group A was 85.23 with an SD of 8.541 
Group B was 81.47 with an SD of 7.651 
The P value of baseline heart rate correlation for both groups was 
0.77 which is greater than 0.05 and hence statistically not significant. 
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Table 12: 
 
The mean post intubation heart rate for group A was 80.07 with an 
SD of 7.437 
The mean post intubation heart rate for group B was 114.50 with 
an SD  of 17.729 
The P value is 0.000 which is less than 0.05 and is statistically 
significant 
The difference between the mean of baseline heart rate and post 
intubation heart rate in group A was a reduction by  5.1. 
Group B was a increase by 33.03 
Thus the variation in heart rate is minimal for group A than group B 
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MEAN ARTERIAL PRESSURE DATA DISTRIBUTION: 
Table 13: 
 
The data regarding mean arterial pressure at baseline and post 
intubation for both groups were analyzed using t-test 
The mean baseline MAP of 
Group A was 96.70 mm Hg with an SD of 3.544 mmHg 
Group B was 95.60 mm Hg with an SD of 4.090 mm Hg 
The P value for baseline MAP correlation for both groups was 
0.270 which is greater than 0.05 and hence statistically not significant 
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Table 14: 
 
The mean post intubation MAP  for , 
Group A was 99.27 with an SD of 5.489 
Group B was 113.87 with an SD OF 4.622 
The P value for the post intubation MAP correlation for both 
groups was 0.000 which is less than 0.05 which is statistically significant. 
The difference between the mean of baseline MAP and post 
intubation MAP in 
Group A was an increase by 2.57 mm Hg 
Group B was an increase by 18.27 mm Hg 
Thus the variation in mean arterial pressure is minimal for group A 
than group B. 
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DISCUSSION 
The thrust to move away from Invasive techniques (Tracheotomy/ 
Tracheostomy) to Non invasive techniques has given rise to an array of 
techniques like Laryngoscopy, Orotracheal Intubation and more recently 
Fibre Optic Intubation in Modern anaesthetic care. The arrival of 
Laryngoscope blades and the subsequent orotracheal intubation has been 
the Mainstay of Non invasive airway Management since the last century. 
However, Orotracheal intubation using Laryngoscopy in an Anesthetized 
patient could not be performed in all patients especially in patients with 
difficult airway and it posed a variety of difficulties which are as follows: 
i. Loss of Muscle tone and the subsequent collapse of soft tissues 
of the airway leading to airway obstruction. 
ii. Desaturation events are high in an anesthetized patients and 
difficult to intubate scenarios 
The recent use of Fiberoptic bronchoscope for intubation in an 
awake state under conscious sedation can overcome the previously 
enlisted difficulties. The awake state of the patients enables the preserved 
muscle tone of the soft tissues of the airway maintaining its patency, less 
desaturation events, spontaneous breathing opens up airway leading to 
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easier intubation. Further, in those with difficult airways, FOB intubation 
could be successfully performed. 
The history of Fiberoptic intubation can be traced to the last few 
decades of the 20th century. In 1967, a choledocoscope was first used to 
intubate a patient with still’s disease (35). The use of Fiberoptic 
intubation then was mainly for diagnostic purpose of airway conditions 
and in recent times, Fiberoptic bronchoscopy intubation has become the 
First choice of intubation in difficult airway cases. 
Endotracheal intubation in an awake state, if performed without 
adequate sedation can be an unpleasant and discomforting experience for 
the patient. The various drugs used for sedation during AFOI are as 
follows:- 
i. Benzodiazepine (Midazolam) 
ii. Propofol 
iii. Alpha 2 agonists (clonidine &Remifentanyl) 
iv. Ketamine 
The above mentioned drugs can be used alone or in combination 
with others and in various dosages as per the requirements of the patient, 
clinical settings, operative conditions. An ideal sedative regimen for 
AFOI should provide, 
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i. Patient comfort & co operation 
ii. Amnesia 
iii. Anxiolysis 
iv. Anti tussive properties / Attenuation of airway Reflexes 
v. Stable hemodynamics 
vi. Maintenance of a patent airway 
The search for an Ideal sedative regimen for Awake Fibre optic 
Intubation is being constantly pursued by various clinical studies. This 
study aims to compare the efficacy and efficiency of Dexmedetomidine 
and Fentanyl for sedation for AFOI. 
Dexmedetomidine is a highly selective alpha 2 agonist mainly 
acting upon the pontine Locus coeruleus nucleus producing sedation. 
Further, it has Anxiolytic, Analgesic and Anti sialogogue properties. An 
important property of Dexmedetomidine is that it produces sedation 
without respiratory depression; in contrast opioid agonists produce 
respiratory depression along with sedation. 
Fentanyl is a highly selective opioid u receptor agonist producing 
sedation, analgesia. It has Antitussive properties. At a dose of 1 to 2 
ug/kg, it decreases respiratory rate and increases tidal volume. At a dose 
of 3 ug/kg or above, Fentanyl decreases both the respiratory rate and  
tidal volume, further, it attenuates the ventilatory drive. 
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STUDY DESIGN: 
In the context of the above, we have undertaken a study to compare 
the efficacy and efficiency of Dexmedetomidine (1 ug/kg over 10 min) 
and Fentanyl (2 ug/kg over 10 min) for sedation for Awake Fiberoptic 
intubation. 
A total of 60 patients with ASA – PS I & II with Mallampati 
grading I & II posted for elective surgery undergoing general anaesthesia 
in  Government Theni Medical college, Theni were selected for the study. 
A well informed written consent was obtained from all of them. 
The patients were randomly allotted into two groups with 30 
patients each. 
i. Group A (n = 30) – received study drug Inj. 
Dexmedetomidine (1 ug/kg over 10 min) 
ii. Group B (n = 30) = received study drug Inj. Fentanyl (1 
ug/kg over 10 min) 
All patients had been counselled about the procedure and were 
premedicated with drugs T. Alprazolam 0.5 mg the night before the 
surgery, T.Ranitidine 150 mg and T. Ondansetron 4 mg were given 2 
hours before the surgery. Inj. Glycopyrrolate 0.2 mg IV. Topical 
anaesthesia of the airway was achieved with Nebulisation of 2% lidocaine 
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4 ml over 20 minutes. Then as per the patients grouping, study drug Inj. 
Dexmedetomidine Infusion at a dose of 1ug/kg over 10 min was given to 
Group A and Inj. Fentanyl at a dose of 2ug/kg over 10 min was given to 
Group B. The nostrils were prepared with xylometazoline drops and 
lidocaine jelly. At the end of study drug Infusion, the level of sedation 
was assessed using the Ramsay sedation score. An RSS >=2 was 
considered appropriate before Intubation. If the sedation of RSS >=2 
could not be achieved, Inj. Midazolam as a rescue sedation was used. A 
well lubricated Fiberoptic bronchoscope preloaded with the appropriate 
ETT was inserted through the Nasal route and Intubation was 
successfully performed in all the patients. 
Intubation condition was assessed by COUGH SCORE during 
bronchoscopy. Tolerance to intubation was assessed by the POST 
NTUBATION SCORE. The Mean Arterial Pressure and the Heart Rate 
of the patient was recorded at the Baseline before the intubation and after 
the intubation. Oxygen saturation using SpO2 was monitored throughout 
the Intubation procedure and the lowest reading was noted. 
All the recordings were tabulated and statistical analysis was done. 
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INTERPRETATION OF RESULTS 
1. Age, Sex, Weight, ASA – PS correlation: 
Both the Groups A & B are comparable in terms of the patients 
Demographic characteristics like Age (P value 0.725 > 0.05), sex (p value 
1.000 > 0.05), weight (P value 0.623 > 0.05), ASA - PS (P value 0.718 > 
0.05) and no statistical significance between the two groups exist in terms 
of the above mentioned criteria. 
2. Cough Score correlation: 
A cough score of less than or equal to 2 was considered as a 
favourable intubation condition. In this study, cough score <= 2 was 
achieved in 27 patients out of 30 patients in Group A whereas in only 3 
out of 30 patients in Group B. The difference is statistically significant (P 
value 0.001 < 0.005). Thus cough score was significantly favourable in 
Group A than Group B. 
3. Post Intubation Score correlation: 
The best post intubation score of 1 (co operative) was achieved in 27 
out of 30 patients in Group A whereas in only 3 out of 30 patients in 
Group B. The difference is statistically significant (P value 0.002 < 0.05). 
Thus, the post intubation score is significantly favourable for Group A 
than Group B. 
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Chu et al had observed better tolerance of endotracheal intubation without 
upper airway obstruction and respiratory depression in the 
Dexmedetomidine group (1ug/kg) compared with the Fentanyl group 
(1ug/kg)(36). 
Bergere et al has observed that Dexmeditomidine in combination 
with low dose Midazolam is more effective than Midazolam alone for 
sedation in Awake Fiberoptic Intubation and that Dexmedetomidine at 
1ug/kg bolus was safe and beneficial for patients undergoing Awake 
Fiberoptic intubation even without airway nerve block or topical 
Anaesthesia (37). 
Further, Dexmedetomidine has been proved as an effective sedative 
agent for AFOI in difficult airway scenarios (38) 
4. Ramsay sedation score correlation: 
A Ramsay sedation score of >=2 was considered appropriate for 
intubation. In our study, 80% of patients in Group A (24 out of 30 
patients) could achieve a higher RSS Score of 3 where as 83.3% of 
patients in Group B (25 out of 30 patients) achieved the Lower RSS 2. 
The difference is statistically significant (P value 0.004 < 0.05). Thus 
Ramsay sedation score is significantly favourable for Group A than 
Group B. Further, in 2 patients in Group B, the Ramsay sedation score 
was  1 (Anxious, Agitated or Restless), so Inj. Midazolam was used as a 
Rescue sedation. 
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5. Oxygen saturation, Heart Rate, Mean Arterial Pressure 
correlation: 
The mean SpO2 in Group A was 96.60% with an SD of 1.653% 
whereas in Group B, it was 93.10% with an SD of 2.107%. The 
difference is statistically significant (P value 0.000 < 0.05). Thus, 
desaturation events are significantly less in Group A than Group B. The 
Desaturation events are managed by administering oxygen through the 
bronchoscope port. 
The mean Base line Heart Rate in Group A was 85.23 with an SD 
of 8.541 and in  Group B was 81.47 with an SD of 7.651. 
The mean Post intubation Heart Rate in Group A was 80.07 with 
an SD of 7.437 and in Group B was 114.50 with an SD of 17.729. 
Thus there was significant change in the Heart Rate in Group B 
between baseline and post intubation recordings while in Group A, there 
was no significant changes. The difference is statistically significant (P 
value 0.000 < 0.05). 
There was no incidence of bradycardia in any of the patients in 
both the groups. However, it has to be noted that in Group A, the mean 
Baseline HR reduced by 5.16 in the post intubation recording. This can be 
attributed to Dexmedetomidine causing decreased Nor adrenaline release, 
decreased centrally mediated sympathetic tone and increased vagal 
activity. 
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Peden et al observed bradycardia and sinus arrest in young 
volunteers following Dexmeditomidine bolus and infusion(39). Since, in 
this study, Inj. Glycopyrrolate was administered as an anti sialogogue, the 
reduction response of Heart Rate to Dexmeditomidine may have been 
attenuated to a significant extent. 
The Mean Baseline MAP for Group A was 96.70 mmHg with an 
SD of 3.544 mmHg and in Group B was 95.60 mmHg with an SD of 
4.090 mmHg. 
The Mean Post intubation MAP for Group A was 99.27 with an SD 
of 5.489 and in Group B was 113.87 with an SD of 4.622. 
Thus, it can be seen that there is significant changes in MAP 
between baseline and post intubation recordings in Group B whereas no 
significant change was observed in Group A. The difference is 
statistically significant (0.000 < 0.05). 
Venn et al reported unaltered hemodynamics even in higher doses 
of Dexmedetomidine Infusion(40). 
To summarize, Dexmedetomidine is more effective than Fentanyl 
during Awake Fiberoptic intubation, as it provides better sedation, patient 
comfort, better intubation condition, Hemodynamic stability and less 
desaturation. 
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SUMMARY 
We conducted a comparative study of Inj. Dexmedetomidine 
(1ug/kg over 10 min) and Inj. Fentanyl (2ug/kg over 10 min) for better 
sedation and patient comfort in those undergoing elective Awake 
Fiberoptic Intubation. A total of 60 patients were selected for the study 
and they were randomly categorized into Group A and Group B. All 
patients are premedicated with T. Ranitidine 150mg and T. Ondansetron 
4mg  2 hours before surgery and all received Inj. Glycopyrrolate 0.2mg as 
Anti Sialogogue. Group A received study drug Inj. Dexmedetomidine at a 
dose of 1ug/kg over 10 min and Group B received Inj. Fentanyl at a dose 
of 2 ug/kg over 10 min. The level of sedation was evaluated using 
Ramsay sedation score and the Intubation condition were evaluated using 
cough score during bronchoscopy. Tolerance to intubation was evaluated 
by the Post intubation score after successful placement of endotracheal 
tube in the trachea. Further, oxygen saturation was continuously 
monitored using SPO2. Other Hemodynamic parameters like HR, MAP 
were recorded at the baseline prior to the procedure and post intubation. 
In analysis, we have observed that both Group A and Group B has 
comparable demographic characteristics (Age, sex, weight). Further, 
Ramsay sedation score, cough score, post intubation score were 
significantly favourable in Group A than in Group B. Significantly less 
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desaturation were observed in Group A than Group B. Hemodynamic 
parameters like Heart Rate and Mean Arterial pressure did not show 
significant variability between baseline and post  intubation values in 
Group A when compared with that of Group B. 
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CONCLUSION 
 
In our study, we have shown that Inj. Dexmedetomidine (1ug/kg 
over 10 min) is more effective than Inj. Fentanyl (2ug/kg over 10 min) for 
Awake Fiberoptic Intubation in terms of better sedation, intubating 
conditions and tolerance to intubation. 
 Inj. Dexmedetomidine produces minimal or No respiratory 
depression when compared with that of Inj. Fentanyl resulting in 
less desaturation events than the latter. 
 Hemodynamic changes (HR, MAP) are insignificant with Inj. 
Dexmedetomidine when compared with that of Inj. Fentanyl. 
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PROFORMA 
GOVT THENI MEDICAL COLLEGE AND HOSPITALS 
DEPT OF ANAESTHESIOLOGY 
COMPARISON B/W FENTANYL AND DEXMEDITOMIDINE FOR 
AWAKE FIBROPTIC INTUBATION 
NAME:    AGE/SEX:   IP NO: 
DIAGNOSIS: 
PROCEDURE DONE: 
ASA RISK: 
PREMEDICATION: Inj ranitidine / inj ondnsetrone / inj glycol 
MPG: 
AIRWAY ASESSMENT: 
PATENCY OF BOTH NOSTRILS: 
LIGNOCAINE [4% ML] NEBULISATION: 
PULSE: 
BP: 
SPO2: 
FENTANYL/DEXMEDITOMIDINE: 
RAMSAY SEDATION SCORE: 1/2/3/4/5/6 
LIGNOCAINE 10% SPRAY: 
ETT: 
COUGH SCORE: [INTUBATING CONDITION] – 1/2/3/4 
POST INTUBATION SCORE: 1/2/3 
PULSE: 
BP: 
SPO2: 
COMPLICATIONS IF ANY AND MANAGEMENT: 
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MASTER CHART 
GROUP – A DEXMEDETOMIDINE 
S.NO AGE WEIGHT 
ASA-
PS 
COUGH 
SCORE 
POST 
INTUBATION 
SCORE 
RAMSAY 
SEDATION 
SCORE 
SPO2 
BASELINE 
HR  
POST 
INTUBATION 
HR 
BASE 
LINE 
MAP 
POST 
INTUBATION 
MAP 
1. 33/M 64 I 2 1 3 97% 100 90 99 97 
2. 37/M 70 I 2 2 3 98% 90 85 102 106 
3. 32/M 65 I 2 1 3 98% 98 75 93 87 
4. 41/M 52 II 1 1 3 97% 78 65 96 86 
5. 49/F 58 I 2 1 2 96% 98 90 101 100 
6. 25/M 60 I 2 1 3 94% 90 86 97 93 
7. 31/M 58 I 3 1 2 97% 94 90 98 103 
8. 30/F 54 I 2 1 3 97% 83 86 93 107 
9. 47/M 66 II 2 1 2 97% 74 70 94 98 
10. 36/F 64 I 2 1 3 98% 83 79 95 101 
11. 24/M 71 I 2 1 4 92% 95 89 100 106 
12. 46/M 63 I 2 1 3 99% 88 82 103 101 
13. 27/M 55 I 2 1 3 96% 74 71 96 101 
14. 33/F 66 I 3 1 3 97% 78 70 93 97 
15. 28/M 57 I 2 1 3 99% 93 90 95 104 
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16. 37/F 67 I 2 1 3 96% 81 76 97 99 
17. 44/M 69 I 1 2 3 95% 88 82 91 96 
18. 25/F 56 I 2 1 3 98% 102 91 90 93 
19. 31/M 65 II 2 1 3 96% 88 83 99 104 
20. 26/M 62 I 2 1 3 97% 79 80 96 101 
21. 35/F 73 I 2 1 2 97% 84 80 100 102 
22. 48/F 63 I 2 1 3 93% 74 78 94 96 
23. 36/F 77 I 2 1 3 96% 86 81 96 92 
24. 24/F 68 I 2 1 3 98% 91 88 94 97 
25. 46/M 71 II 3 1 3 95% 78 71 98 99 
26. 23/F 66 I 2 1 3 96% 83 79 97 104 
27. 26/M 58 I 2 2 3 99% 74 70 95 98 
28. 28/F 62 I 2 1 4 96% 81 78 95 98 
29. 43/F 63 II 2 1 3 98% 72 74 106 110 
30. 39/M 74 I 2 1 3 96% 80 73 98 102 
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GROUP – B FENTANYL 
S.NO AGE WEIGHT 
ASA-
PS 
COUGH 
SCORE 
POST 
INTUBATION 
SCORE 
RAMSAY 
SEDATION 
SCORE 
SpO2 
BASELINE 
HR 
POST 
INTUBATION 
HR 
BASELINE 
MAP 
POST 
INTUBATION 
MAP 
1. 47/M 66 II 3 2 2 93% 68 101 97 116 
2. 28/F 52 I 3 2 1 91% 80 100 88 108 
3. 25/F 55 I 3 2 2 97% 90 114 93 110 
4. 30/M 70 I 3 3 2 94% 102 112 97 112 
5. 22/M 58 I 3 2 3 90% 79 89 89 105 
6. 21/M 65 I 3 2 2 92% 72 108 94 106 
7. 39/M 74 I 2 2 2 94% 91 107 89 109 
8. 24/F 58 I 3 2 2 96% 79 101 103 118 
9. 38/M 66 II 3 1 2 89% 78 118 98 115 
10. 26/F 58 I 3 2 2 93% 84 112 97 113 
11. 33/M 62 I 3 2 2 92% 91 122 104 115 
12. 25/M 73 I 3 2 2 94% 83 117 94 110 
13. 34/M 68 I 3 2 3 91% 77 109 96 116 
14. 42/F 55 I 3 2 2 93% 73 106 93 111 
15. 38/M 65 I 3 2 2 96% 81 116 97 116 
16. 23/F 69 I 3 2 2 94% 90 122 91 110 
17. 37/M 58 I 3 2 2 93% 70 104 94 116 
18. 47/M 63 II 2 2 2 94% 79 111 99 120 
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19. 38/F 69 I 3 1 1 91% 88 124 101 123 
20. 31/M 78 I 3 2 2 90% 75 198 89 109 
21. 26/F 58 I 3 2 2 94% 84 120 94 117 
22. 33/F 64 I 3 2 2 98% 80 117 95 112 
23. 43/M 69 I 3 2 2 90% 76 118 97 113 
24. 28/M 63 I 3 3 2 92% 93 117 93 118 
25. 42/F 74 I 3 2 2 93% 73 108 102 119 
26. 29/F 67 I 3 3 2 94% 81 126 96 115 
27. 36/M 64 I 3 2 3 93% 76 109 98 116 
28. 47/F 63 I 3 2 2 94% 79 107 94 118 
29. 33/M 66 I 2 1 2 93% 88 114 97 122 
30. 43/F 71 II 3 2 2 95% 84 108 99 108 
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